Gender-Affirming Hormone Therapy for Transgender Females.

  title={Gender-Affirming Hormone Therapy for Transgender Females.},
  author={John F. Randolph},
  journal={Clinical Obstetrics \& Gynecology},
  • J. Randolph
  • Published 1 December 2018
  • Medicine
  • Clinical Obstetrics & Gynecology
The provision of hormone therapy, both estrogens and antiandrogens, to adult transgender females is well within the scope of practice of the obstetrician gynecologist. The goal is to induce feminizing changes and suppress previously developed masculinization. Estrogens in sufficient doses will usually achieve both goals with augmentation by antiandrogens. The primary short-term risk of estrogens is thrombosis, but long-term risk in transgender females is unclear. Optimal care requires… Expand
7 Citations
Transgender health: Hormonal management at 50 years and beyond.
This review discusses established transgender individuals on hormones who have reached their desired post-pubertal phenotype and recommended maintenance therapy and safety evaluation to mitigate the risks of hormone therapy with a focus on the older population. Expand
Medical Transition for Gender Diverse Patients
High-quality, long-term studies on the effectiveness and safety of various gender-affirming hormone treatment regimens are lacking, but the currently available evidence suggests that it is overall safe and effective with appropriate oversight. Expand
Fertility preservation options for transgender and gender-nonconforming individuals
  • M. Moravek
  • Medicine
  • Current opinion in obstetrics & gynecology
  • 2019
There is currently a paucity of data on the fertility effects of gender-affirming hormones, necessitating fertility preservation counseling prior to initiation of therapy and several modifications can be made to fertility preservation protocols and procedures to decrease gender dysphoria or distress in transgender individuals. Expand
Pathology of breast lesions in female transgender
Hormonal action or prosthesis implantation in female transgender can lead to associated pathologies in the mammary gland that follow a similar pattern to that found in the male breast. Expand
Hormonothérapie féminisante chez les femmes transgenres
Resume Les mouvements de lutte et de liberation sociale depuis les annees 1960 ont permis tres progressivement aux communautes LGBTQI+ d’acceder a une prise en charge medicale adaptee a leurs besoinsExpand
Southern African HIV Clinicians’ Society gender-affirming healthcare guideline for South Africa
No abstract available.


Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons.
Hormonal and surgical therapies improve quality of life and mental health with minimal adverse effects and Ongoing research is needed to improve understanding about specific risks of hormone therapy and surgical outcomes. Expand
Hormone Treatment of the Adult Transsexual Patient
  • L. Gooren
  • Medicine
  • Hormone Research in Paediatrics
  • 2005
The goal of treatment in female-to-male transsexuals is to induce virilization, including a male pattern of sexual hair, a male voice and male physical contours, and to stop menses. Expand
Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.
Cross-sex hormone treatment of transsexuals seems acceptably safe over the short and medium term, but solid clinical data are lacking. Expand
Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.
The range of treatment used by transsexual people, the rationale behind these, and the expectation from such treatment are discussed, as well as the potential adverse effects of cross-sex hormone treatment of transsexual people. Expand
Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy
Cross-sex hormone therapy (CSHT), particularly with testosterone, is associated with worsening cardiovascular risk factors in transgender men but not with increases in cardiovascular morbidity or mortality, and the literature regarding the association between CSHT and CVD in transgender adults is summarized. Expand
Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism
The clinical and hormonal response to 12-month therapy with the antiandrogen, spironolactone, in conjunction with near-physiologic doses of female gonadal steroids in 50 transsexual males, isExpand
Medical Management of Adult Transsexual Persons
Methods, including both pharmacotherapy and surgical interventions, are described for effective medical management of both male and female adults with GID, an increasingly recognized medical condition with an expanding body of medical literature to support the use of established therapeutic guidelines. Expand
Mortality and morbidity in transsexual subjects treated with cross‐sex hormones
Investigation of mortality and morbidity figures in a large group of transsexual subjects receiving cross‐sex hormone treatment finds that the optimum steroid hormone treatment regimes for transsexual subjects has not yet been established. Expand
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit. Expand
Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons
This objective was to compare ACVE incidence rates in a cohort of transgender persons enrolled in 3 such health care systems with rates observed in age-, race-, site-, and membership-matched cisgender men and women (reference cohorts). Expand